AIDS Funds: Rwanda

摘要

In Their Policy Forum "Global Hiv/Aids policy in transition" (11 June, p. 1359), J. Bongaarts and M. Over conclude that anti-retroviral therapy for AIDS is not a cost-effective use of donor funding for global health. We believe that Bongaarts and Over omitted key aspects of a complete cost-effectiveness assessment: numerous positive spinoffs to other services, the effect on increased attention on global health, and the ability to mobilize resources that would not otherwise have been available for global health.